drugset
drugset / Trial / NCT05563012

Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma

NCT05563012 ↗

Phase 2 Recruiting 29 enrolled Renmin Hospital of Wuhan University
NaSingle-groupOpen-labelTreatment

Summary

This is a Prospective, Single-center, Single-arm, phase II clinical trial to explore the efficacy and safety of sintilimab (PD1 inhibitor) combined with XELOX chemotherapy, evaluate the pathological complete response rate of short-course radiotherapy combined with sintilimab and XELOX chemotherapy in neoadjuvant therapy for locally advanced gastric adenocarcinoma.

Timeline

Start
2022-09-26
Primary completion
2025-10-01
Completion
2026-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimal Unknown 200 mg Intravenous
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

No indication recorded.